Disease · HP_0000855
Insulin resistance
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Insulin resistance. Diseases, record HP_0000855. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0000855
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Insulin resistance
- Open Targets ID
- HP_0000855
- Other names
- Body fails to respond to insulin, Drug resistance to insulin (disorder), IR
- Highest stage of its drugs
- Phase 3, for 14 of its 118 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs118
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| METFORMIN | CHEMBL1431 | Small molecule | Phase 3 | ClinicalTrials.gov | 27 | 27 | 27 | Drugs and targets |
| PIOGLITAZONE | CHEMBL595 | Small molecule | Phase 3 | ClinicalTrials.gov | 20 | 20 | 20 | Drugs and targets |
| ROSIGLITAZONE | CHEMBL121 | Small molecule | Phase 3 | ClinicalTrials.gov | 11 | 11 | 11 | Drugs and targets |
| TESTOSTERONE | CHEMBL386630 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| METFORMIN HYDROCHLORIDE | CHEMBL1703 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| SITAGLIPTIN | CHEMBL1422 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| TADALAFIL | CHEMBL779 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| ATORVASTATIN | CHEMBL1487 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| FISH OIL | CHEMBL3833369 | Phase 3 | ClinicalTrials.gov | 2 | 2 | 1 | Drugs and targets | |
| ACETYLCYSTEINE | CHEMBL600 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
1 to 10 of 118
See all 118 drugsTargets155
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| GNRHR | Gonadotropin-releasing hormone receptor | 4 | Gonadotropin-releasing hormone receptor agonist | Phase 2 | https://conductscience.org/library/genes/2798 | Drugs and targets |
| AGTR1 | Type-1 angiotensin II receptor | 3 | Type-1 angiotensin II receptor antagonist | Unknown | https://conductscience.org/library/genes/185 | Drugs and targets |
| PPARA | Peroxisome proliferator-activated receptor | 3 | Peroxisome proliferator-activated receptor agonist; Peroxisome proliferator-activated receptor alpha agonist | Phase 2/3 | https://conductscience.org/library/genes/5465 | Drugs and targets |
| PPARD | Peroxisome proliferator-activated receptor | 3 | Peroxisome proliferator-activated receptor agonist; Peroxisome proliferator-activated receptor delta agonist | Phase 2/3 | https://conductscience.org/library/genes/5467 | Drugs and targets |
| PPARG | Peroxisome proliferator-activated receptor | 3 | Peroxisome proliferator-activated receptor agonist; Peroxisome proliferator-activated receptor gamma agonist | Phase 3 | https://conductscience.org/library/genes/5468 | Drugs and targets |
| ADRA1A | Adrenergic receptor alpha | 2 | Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-1 antagonist | Phase 1 | https://conductscience.org/library/genes/148 | Drugs and targets |
| ADRA1B | Adrenergic receptor alpha | 2 | Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-1 antagonist | Phase 1 | https://conductscience.org/library/genes/147 | Drugs and targets |
| ADRA1D | Adrenergic receptor alpha | 2 | Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-1 antagonist | Phase 1 | https://conductscience.org/library/genes/146 | Drugs and targets |
| ADRB3 | Adrenergic receptor beta | 2 | Adrenergic receptor beta antagonist; Beta-3 adrenergic receptor agonist | Early phase 1 | https://conductscience.org/library/genes/155 | Drugs and targets |
| COXFA4 | Mitochondrial complex I (NADH dehydrogenase) | 2 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Phase 3 | https://conductscience.org/library/genes/4697 | Drugs and targets |
1 to 10 of 155
See all 155 targetsTrials181
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 6 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00001723 | Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases | Phase 2 | 200 | 2012-12-18 | Diabetes Mellitus, Hypertension, Metabolic Disease, Obesity, Sleep Apnea Syndrome | ORLISTAT | Its record names the disease | ClinicalTrials.gov |
| NCT02819440 | PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction | Phase 2 | 141 | 2022-05-27 | Healthy, Obese | TADALAFIL | Its record names the disease | ClinicalTrials.gov |
| NCT02168660 | Correction of Vitamin D Levels and Its Effect on Insulin Resistance and Weight Gain in Obese Youth | Phase 2 | 109 | 2019-12-09 | Obesity, Insulin Resistance, Vitamin D Deficiency | CHOLECALCIFEROL | Its record names the disease | ClinicalTrials.gov |
| NCT03117517 | Treatment With Metformin and Combination of Metformin and Pioglitazone in Polycystic Ovarian Syndrome | Early phase 1 | 106 | 2020-03-02 | Polycystic Ovarian Syndrome | METFORMIN, PIOGLITAZONE | Its record names the disease | ClinicalTrials.gov |
| NCT00771901 | Effect of Endoplasmic Reticulum Stress on Metabolic Function | Not applicable | 101 | 2018-05-29 | Insulin Resistance, Diabetes, Obesity | SODIUM PHENYLBUTYRATE, TAURURSODIOL | Its record names the disease | ClinicalTrials.gov |
| NCT00005669 | Metformin to Treat Obesity in Children With Insulin Resistance | Phase 2 | 100 | 2011-04-07 | Hyperinsulinemia, Obesity | METFORMIN | Its record names the disease | ClinicalTrials.gov |
| NCT01301027 | Effect of Adipokines in Hemodialysis Patients | Not applicable | 95 | 2016-10-03 | End Stage Renal Disease | PIOGLITAZONE | Its record names the disease | ClinicalTrials.gov |
| NCT00130286 | Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance | Phase 1/2 | 77 | 2014-02-13 | HIV-Associated Lipodystrophy Syndrome, Insulin Resistance, HIV Infections, Metabolic Syndrome X, Body Weight Changes | ROSIGLITAZONE, SOMATROPIN | Its record names the disease | ClinicalTrials.gov |
| NCT02153983 | Effects of Colchicine in Non-Diabetic Adults With Metabolic Syndrome | Phase 1/2 | 77 | 2019-08-13 | Obesity, Metabolic Disease | COLCHICINE | Its record names the disease | ClinicalTrials.gov |
| NCT01444651 | A Trial of Tadalafil and Glycemic Traits | Phase 3 | 73 | 2017-01-30 | Cardiovascular Disease, Insulin Resistance, Glucose Intolerance, Obesity | TADALAFIL | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 181
See all 181 trialsComparisons in its trials51
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Orlistat vs Placebo: serious adverse events | 0 of 100 | 2 of 100 | 200 | NCT00001723 | Trial comparisons |
| Tadalafil vs Placebo: deaths from any cause | 0 of 61 | 0 of 64 | 125 | NCT02819440 | Trial comparisons |
| Tadalafil vs Placebo: serious adverse events | 0 of 61 | 0 of 64 | 125 | NCT02819440 | Trial comparisons |
| Metformin Plus Weight Reduction Counseling vs Placebo Plus Weight Reduction Counseling: serious adverse events | 0 of 53 | 0 of 47 | 100 | NCT00005669 | Trial comparisons |
| Pioglitazone vs Placebo: serious adverse events | 11 of 48 | 10 of 47 | 95 | NCT01301027 | Trial comparisons |
| Tadalafil vs Placebo: serious adverse events | 0 of 36 | 0 of 37 | 73 | NCT01444651 | Trial comparisons |
| Salsalate Therapy vs Placebo: serious adverse events | 0 of 34 | 0 of 36 | 70 | NCT00330733 | Trial comparisons |
| Diet Intervention vs GLP-1 Intervention: deaths from any cause | 0 of 17 | 0 of 38 | 55 | NCT03919929 | Trial comparisons |
| Diet Intervention vs GLP-1 Intervention: serious adverse events | 0 of 17 | 0 of 38 | 55 | NCT03919929 | Trial comparisons |
| Pitavastatin vs Placebo: deaths from any cause | 0 of 25 | 0 of 25 | 50 | NCT02290106 | Trial comparisons |
1 to 10 of 51
See all 51 comparisons in its trialsPapers from its trials116
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0000855
GET https://conductscience.org/api/diseases/v1/HP_0000855/drugs?page=2